Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age2+
SponsorNational Cancer Institute (NCI)
About this trial
Selected individuals suspected of having or with prior biopsy proof of malignant disease will be seen in the Urologic Oncology Branch, NCI. Blood samples may be collected at the time of the initial visit and at periodic intervals during the course of the disease. These samples will be stored in the tissue bank of the Urologic Oncology Branch. Aliquots of malignant and normal tissue will be collected at the time of surgery and stored in the tissue bank, Urologic Oncology Branch, NCI. These materials will be used in the research efforts of the Urologic Oncology Branch, NCI.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Individuals with biopsy-proven malignant disease
Individuals suspected of having a malignant disease
Individuals who have or are suspected of having an inherited genitourinary malignant disorder
Participants must be >= 2 years of age
Disqualifiers
None
Trial population
1\. Individuals with biopsy-proven malignant disease 2. Individuals suspected of having malignant disease 3. Individuals with known or suspected urologic malignant disorders who have clinically indicated urologic or non-urologic surgical lesion 4. Family members of individuals suspected of having an inherited genitourinary malignancy 5. Family members of individuals with a DNA variant
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
5,950 Participants
are grouped into 2 trial groupsGroup A: Family Members
Group B: Participants
Trial outcomes
Primary outcomes
1
Investigate quality of life in men who have prostate cancer.
Prostate cancer participants that have improvement in quality of life
Time frame
on-going2
Investigate molecular genetic basis of urologic malignancies
Investigate molecular genetic basis of urologic malignancies
Time frame
on-going3
Investigate cellular/biochemical response to existing and novel therapeutic agents.
Collection of blood, urine, saliva, and/or benign and malignant tissue
Time frame
on-going4
Examine protein expression and bioimmunoassays investigating potential genetic markers.
Detection and expression analysis of gene(s)
Time frame
on-goingSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov